Pyk2 is overexpressed in many cancers (43) and Pyk2 inhibition attenuated survival and proliferation of small cell lung cancer (66), breast cancer (80), ovarian clear cell cancer (85), multiple myeloma (88), and prostate cancer (31). Here, PTK2B is linked to prostate cancer.